1122 1113

Cited 0 times in

Daratumumab 투여를 받은 다발성 골수종 환자에서 비예기항체 동정검사상 범응집 소견을 보인 1예

DC Field Value Language
dc.contributor.author김대원-
dc.contributor.author김진석-
dc.contributor.author김현옥-
dc.contributor.author나현진-
dc.contributor.author이은경-
dc.contributor.author조주영-
dc.date.accessioned2017-10-26T07:44:39Z-
dc.date.available2017-10-26T07:44:39Z-
dc.date.issued2016-
dc.identifier.issn1226-9336-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/152460-
dc.description.abstractHerein, we report a patient showing panagglutination in the unexpected antibody identification test after the administration of daratumumab. The patient was a 66-year-old woman who had undergone multiple cycles of chemotherapy and autologous peripheral blood stem cell transplantation for treating multiple myeloma; however, despite treatment, she had relapsed. Therefore, daratumumab, on clinical trials in Korea, started to be administered. After administration of daratumumab, the result of antibody screening test was positive, on the contrary to the result prior to the administration. Moreover, all positive reactions were shown in the antibody identification to the panel cells. After destroying CD38 antigens on the surface of RBCs using DTT, negative results were obtained. Daratumumab?a novel therapeutic human CD38 monoclonal antibody that can be used as targeted immunotherapy?is an FDA-approved drug for treating multiple myeloma. Because CD38 is expressed not only on myeloma cells, but also on red blood cells (RBCs), the use of daratumumab might lead to RBC agglutinations, and thereby resulting in false-positive results on the pre-transfusion tests. Therefore, caution is needed in case of a patient receiving daratumumab. Furthermore, additional test using DTT is required, especially when panagglutination was shown in the antibody identification test, as in this case.-
dc.description.statementOfResponsibilityopen-
dc.languageKorean-
dc.publisher대한수혈학회-
dc.relation.isPartOfKorean Journal of Blood Transfusion (대한수혈학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleDaratumumab 투여를 받은 다발성 골수종 환자에서 비예기항체 동정검사상 범응집 소견을 보인 1예-
dc.title.alternativeA Case of Panagglutination on Antibody Identification in a Multiple Myeloma Patient Receiving Daratumumab-
dc.typeArticle-
dc.publisher.locationKorea-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Laboratory Medicine-
dc.contributor.googleauthor조주영-
dc.contributor.googleauthor나현진-
dc.contributor.googleauthor김대원-
dc.contributor.googleauthor이은경-
dc.contributor.googleauthor김진석-
dc.contributor.googleauthor김현옥-
dc.identifier.doi10.17945/kjbt.2016.27.2.164-
dc.contributor.localIdA01017-
dc.contributor.localIdA01122-
dc.contributor.localIdA04555-
dc.contributor.localIdA04783-
dc.contributor.localIdA04684-
dc.contributor.localIdA04888-
dc.relation.journalcodeJ01970-
dc.subject.keywordDaratumumab-
dc.subject.keywordCD38-
dc.subject.keywordPanagglutination-
dc.subject.keywordDithiothreitol (DTT)-
dc.contributor.alternativeNameKim, Dae Won-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.alternativeNameKim, Hyun Ok-
dc.contributor.alternativeNameNah, Hyunjin-
dc.contributor.alternativeNameLee, Eunkyung-
dc.contributor.alternativeNameCho, Jooyoung-
dc.contributor.affiliatedAuthorKim, Jin Seok-
dc.contributor.affiliatedAuthorKim, Hyun Ok-
dc.contributor.affiliatedAuthorNah, Hyunjin-
dc.contributor.affiliatedAuthorLee, Eunkyung-
dc.contributor.affiliatedAuthorCho, Jooyoung-
dc.contributor.affiliatedAuthorKim, Dae Won-
dc.citation.volume27-
dc.citation.number2-
dc.citation.startPage164-
dc.citation.endPage168-
dc.identifier.bibliographicCitationKorean Journal of Blood Transfusion (대한수혈학회지), Vol.27(2) : 164-168, 2016-
dc.date.modified2017-10-24-
dc.identifier.rimsid48663-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.